By physician referral or invitation only

A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients

The purpose of this study is to evaluate the effects of sotatercept treatment (plus background PAH therapy) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Jimmy Ford
Medicine-Pulmonary

Study Type

Clinical or Medical
Interventional

Study Topics

Chronic Conditions
Heart and Circulation
Lungs and Breathing
Rare Diseases

IRB Number

22-2024

ClinicalTrials.gov

NCT04811092

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.